FRLN News and Press, Freeline Therapeutics Holdings plc From 05/31/23

FRONTLINE PLC REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2023 Frontline plc (the “Company” or “Frontline”), today reported unaudited results for the three months ended March 31, 2023: Highlights Highest first quarter profit sinc...

Expect to report initial clinical data for FLT201 in Gaucher disease in third quarter of 2023 FLT201 granted ILAP designation, which aims to accelerate time to market and facilitate patient access in the UK for medicines that address significant unmet needs Regained compliance w...

Frontline plc.’s preliminary first quarter 2023 results will be released on Wednesday May 31, 2023, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at&...

LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that FLT201 has been awarded the Innovation Passport for the treatment of Gaucher disease type 1 under the Innovative Licensing and Access Pathway (ILAP) process by the U.K. Medicines an...

LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the company’s previously disclosed change to its American Depositary Share (“ADS”) to ordinary share ratio has been made effective prior to the open of business...

Frontline plc (the “Company”) announces the filing of its annual report for the year ended December 31, 2022. The annual report can be downloaded from the Company’s website www.frontlineplc.cy or from the link below. Additionally, shareholders can request a hard copy of o...

2023-04-21 07:20:12 ET Freeline Therapeutics ( NASDAQ: FRLN ) plans to implement a change in the ratio of its American Depositary Shares to its ordinary shares, effective on or about May 12, 2023. The ratio will be changed from one (1) ADS to one (1) ordinar...

LONDON, April 21, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value £0.00001 per share...

LONDON, April 12, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that its Chief Executive Officer Michael Parini will present at the 22 nd Annual Needham Virtual Healthcare Conference being held on April 17-20, 2023. The presenta...

2023-04-04 10:31:02 ET Freeline Therapeutics Holdings plc (FRLN) Q4 2022 Earnings Conference Call April 4, 2023 8:00 A.M. ET Company Participants Naomi Aoki - Senior Vice President, Head of Investor Relations & Corporate Communications Michael Parini - Chief Exec...